Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Trautmann-Grill, K. [1 ]
Lonial, S. [2 ]
Nooka, A. K. [2 ]
Thulasi, P. [3 ]
Badros, A. Z. [4 ]
Jeng, B. H. [4 ]
Callander, N. S. [5 ]
Sborov, D. [6 ]
Zaugg, B. E. [7 ]
Popat, R. [8 ]
Degli, Esposti S. [9 ,10 ]
Baron, J. [11 ]
Doherty, A. [12 ]
Lewis, E. [13 ]
Opalinska, J. [11 ]
Paka, P. [11 ]
Piontek, T. [11 ]
Gupta, I [11 ]
Farooq, A., V [14 ]
Jakubowiak, A. [14 ]
机构：
[1] Univ Klinkum Carl Gustav, Dresden, Germany
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA
[4] Univ Maryland, Sch Med, Baltimore, MD USA
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA
[8] Univ Coll London Hosp, NHS Fdn Trust, London, England
[9] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[10] UCL Inst Ophthalmol, London, England
[11] GlaxoSmithKline, Providence, RI USA
[12] GlaxoSmithKline, Collegeville, MN USA
[13] GlaxoSmithKline, Res Triangle Pk, NC USA
[14] Univ Chicago, Med Ctr, Chicago, IL USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep271
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [21] Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
    Paul G. Richardson
    Hans C. Lee
    Al-Ola Abdallah
    Adam D. Cohen
    Prashant Kapoor
    Peter M. Voorhees
    Axel Hoos
    Karrie Wang
    January Baron
    Trisha Piontek
    Julie Byrne
    Scott Richmond
    Roxanne C. Jewell
    Joanna Opalinska
    Ira Gupta
    Sagar Lonial
    Blood Cancer Journal, 10
  • [22] DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Nooka, Ajay
    Stockerl-Goldstein, Keith
    Abonour, Rafat
    Ramaekers, Ryan
    Khot, Amit
    Forbes, Adam
    Lee, Cindy
    Augustson, Bradley
    Spencer, Andrew
    Mateos, Maria-Victoria
    Chopra, Bikramjit
    Rogers, Rachel
    Smith, Deborah A.
    Davidge, Jacqueline
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Yeakey, Anne
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Quach, Hang
    BLOOD, 2020, 136
  • [23] Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
    Cardellino, Anna
    Correll, Julia R.
    Martin, Mona
    Gorsh, Boris
    Sapra, Sandhya
    Popat, Rakesh
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Rifkin, Robert M.
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios A.
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania T. M.
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [25] Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
    Richardson, Paul G.
    Lee, Hans C.
    Abdallah, Al-Ola
    Cohen, Adam D.
    Kapoor, Prashant
    Voorhees, Peter M.
    Hoos, Axel
    Wang, Karrie
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Richmond, Scott
    Jewell, Roxanne C.
    Opalinska, Joanna
    Gupta, Ira
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2020, 10 (10)
  • [26] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
  • [27] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
    Suvannasankha, Attaya
    Bahlis, Nizar J.
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Rocafiguera, Albert Oriol
    Voorhees, Peter M.
    Alonso, Aranzazu Alonso
    Callander, Natalie Scott
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne C.
    Zhou, Xiangdong
    Gupta, Ira V.
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) cytogenetics
    Besemer, B.
    Cohen, A. D.
    Trudel, S.
    Lonial, S.
    Libby, E.
    Lee, H. C.
    Facon, T.
    Nooka, A. K.
    Callander, N.
    Chari, A.
    Gupta, I
    Paul, S.
    Opalinska, J.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [29] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
  • [30] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Potter, Heather A.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Colby, Kathryn
    Jakubowiak, Andrzej
    BLOOD CANCER JOURNAL, 2021, 11 (05)
12345